Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)

Trial Profile

A Phase II, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous cultured kidney tissue cells (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors RegenMedTX
  • Most Recent Events

    • 18 Apr 2019 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
    • 07 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 03 Mar 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top